There's power in knowing
Help your patients get ahead of hereditary cancer.
Why Myriad MyRisk
Myriad myRisk with riskScore blends analysis of genetic risk factors with clinical and cancer family history to deliver the most comprehensive, clinically actionable results to help providers manage their patients’ risk of cancer. This means more of your patients will benefit from valuable information that can make a difference in health outcomes for themselves and for their families.
Know their risk to protect their future
Approximately 1 in 4 patients in the community OBGYN setting may be at risk for hereditary cancer and meet current screening guidelines for testing.1
- 90% of high-risk women are not screened for BRCA1/BRCA22
- Interventions are proven to reduce risk3-6
Accurate Results for Actionable Decisions
Myriad is your trusted advisor. Myriad myRisk Hereditary Cancer Test is a multi-gene panel that determines hereditary cancer risk associated with 8 cancer sites:
Breast | Ovarian | Colorectal | Endometrial
Melanoma | Pancreatic | Gastric | Prostate
Together, with Myriad Women's Health
References
- DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the CommunityPractice Setting. Obstetrics & Gynecology 2018 – published online before print October 10, 2018.
- Bellcross CA, et al. Genet Med. 2015;17(1):43–50.
- Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77–84 (1999).
- Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002).
- Plevritis, S et al. Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA. 295(20), 2374–2384 (2006).
- de Jong, A. E. et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130, 665–671 (2006).
- ACOG Committee Opinion: Hereditary Cancer Syndromes and Risk Assessment, No. 634. June 2015, Reaffirmed 2017.
- Risk assessment, genetic counseling, and genetic testing for BRCA related cancer in women: U.S. Preventive Services Task Force recommendation statement. JAMA. 2019;322(7):652-665. doi:10.1001/jama.2019.10987
- Reference with permission from NCCN: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. Version 1.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed June 8, 2020. Available at http://www.nccn.org.
- Judkins T. et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk; BMC Cancer, 2014.
- U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). BRACAnalysis CDxTM approval letter, December 19, 2014. Retrieved November 7, 2018, from http://www.accessdata.fda.gov/cdrh_docs/pdf14/P140020A.pdf.
- Mersch J, et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. JAMA – published online September 25, 2018.